Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin–neprilysin inhibition in diastolic dysfunction after myocardial infarction
2017-002020-25Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sacubitril + valsartan in diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Primary: Ratio of pulmonary capillary wedge pressure to cardiac index at peak exercise. Started May 2018; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
diastolic dysfunctionheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2017-002020-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002020-25.